课题基金 / 基金详情

项目摘要

项目成果

BRENDA A SCHULMAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Post-translational modification by ubiquitin and ubiquitin-like proteins (ublps) is a predominant cellular regulatory mechanism. Ubiquitination regulates a vast array of biological processes, including cell division, the immune response, and embryonic development. As a result, defects in the ubiquitin pathway are associated with numerous diseases, particularly cancer, and disorders associated with aging, such as neurodegenerative disorders and arid muscle wasting. In addition to ubiquitin, over 10 ublps have been found in higher eukaryotes. Ublps have structures and sequences that closely resemble ubiquitin, but they direct their targets to distinct destinies. Therefore, it is important to understand the molecular bases that define the specificity of the ubiquitination process. Our long-term goal is to understand how ubiquitin and ublps are directed to their particular targets to control processes involved in diseases such as cancers and neurodegenerative disorders. Ubiquitin is ligated to targets by a cascade involving a series of three enzymes in classes known as E1, E2, and E3. Despite the importance of these enzymes, little is known how ubiquitin is selected by ubiquitinating enzymes. We hypothesize that the specificity of ubiquitinating enzymes is dictated by a combination of positive selection for interacting with ubiquitin, and negative selection against the wrong ublp. We are focusing on the E1, E2 and E3 enzymes involved in cell proliferation and involved in regulating tumor suppressor proteins. Because these enzymes are important for cell proliferation, and play roles in pathways that lead to cancers, these enzymes may serve as good targets for anti-mitogenic agents. The recent approval of the proteasome inhibitor Bortezomib (VelcadeTM) for treatment of multiple myeloma underscores the therapeutic potential for targeting enzymes in the ubiquitin, and ublp, pathways, and highlights the importance of understanding the detailed mechanisms and specificities of these enzymes. We plan a multidisciplinary approach that combines biochemical, enzymological and structural analysis of ubiquitinating enzymes, enzymes in ublp conjugation cascades, mutants and complexes, in order to understand the specificity of ubiquitination.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A DUAL E3 MECHANISM FOR RUB1 LIGATION TO CDC53
  • 批准号:
    8361697
  • 项目类别:
  • 资助金额:
    $2.74万
  • 财政年份:
    2011
  • 负责人:
    BRENDA A SCHULMAN
  • 依托单位:
UBCH5B~UBIQUITIN-HECTNEDD4L COMPLEX
  • 批准号:
    8361696
  • 项目类别:
  • 资助金额:
    $2.74万
  • 财政年份:
    2011
  • 负责人:
    BRENDA A SCHULMAN
  • 依托单位:
MOLECULAR ARCHITECTURES OF BTB-CUL3 UBIQUITIN LIGASES
  • 批准号:
    8169289
  • 项目类别:
  • 资助金额:
    $0.52万
  • 财政年份:
    2010
  • 负责人:
    BRENDA A SCHULMAN
  • 依托单位:
ENZYMATIC MECHANISMS OF UBIQUITIN-LIKE PROTEIN CONJUGATION
  • 批准号:
    8169265
  • 项目类别:
  • 资助金额:
    $0.52万
  • 财政年份:
    2010
  • 负责人:
    BRENDA A SCHULMAN
  • 依托单位:
国内基金
海外基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    32170319
  • 项目类别:
    面上项目
  • 资助金额:
    58.00万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    --
  • 项目类别:
    --
  • 资助金额:
    58万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
  • 批准号:
    31372080
  • 项目类别:
    面上项目
  • 资助金额:
    80.0万元
  • 批准年份:
    2013
  • 负责人:
    杨迎伍
  • 依托单位: